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Long-term eﬀ ects of Aβ42 immunisation in Alzheimer’s 
disease: follow-up of a randomised, placebo-controlled 
phase I trial
Clive Holmes, Delphine Boche, David Wilkinson, Ghasem Yadegarfar, Vivienne Hopkins, Anthony Bayer, Roy W Jones, Roger Bullock, Seth Love, 
James W Neal, Elina Zotova, James A R Nicoll
Summary 
Background Immunisation of patients with Alzheimer’s disease with full-length amyloid-β peptide (Aβ42) can clear 
amyloid plaques from the brain. Our aim was to assess the relation between Aβ42 immune response, degree of 
plaque removal, and long-term clinical outcomes.
Methods In June, 2003, consent for long-term clinical follow-up, post-mortem neuropathological examination, or 
both, was sought from 80 patients (or their carers) who had entered a phase I randomised, placebo-controlled trial 
of immunisation with Aβ42 (AN1792, Elan Pharmaceuticals) in September, 2000. The follow-up study was completed 
in September, 2006. Plaques were assessed in terms of the percentage area of the cortex with Aβ immunostaining 
(Aβ load) and in terms of characteristic histological features reﬂ ecting plaque removal. Survival of all 80 individuals 
until severe dementia or death was assessed with a Cox proportional hazard model.
Findings 20 participants—15 in the AN1792 group, ﬁ ve in the placebo group—died before follow-up started. A 
further 22 patients—19 in the AN1792 group, three in the placebo group—died during follow-up. Nine of the 
deceased patients, all in the AN1792 group, had given consent for post-mortem analysis; one of these who did not 
die with Alzheimer’s disease was excluded. In the remaining eight participants who received immunisation and 
who were examined neuropathologically, mean Aβ load was lower than in an unimmunised control group that was 
matched for age at death (2·1% [SE 0·7] in treated participants vs 5·1% [0·9] in controls; mean diﬀ erence 3·0%, 
95% CI 0·6–5·4; p=0·02). Although there was considerable variation in Aβ load and degree of plaque removal 
among immunised participants, the degree of plaque removal varied signiﬁ cantly with mean antibody response 
attained during the treatment study period (Kruskal-Wallis p=0·02). Seven of the eight immunised patients who 
underwent post-mortem assessment, including those with virtually complete plaque removal, had severe end stage 
dementia before death. In the whole cohort, there was no evidence of improved survival (hazard ratio 0·93, 95% CI 
0·43–3·11; p=0·86) or of an improvement in the time to severe dementia (1·18, 0·45–3·11; p=0·73) in the AN1792 
group versus the placebo group.
Interpretation Although immunisation with Aβ42 resulted in clearance of amyloid plaques in patients with 
Alzheimer’s disease, this clearance did not prevent progressive neurodegeneration.
Funding Alzheimer’s Research Trust, Medical Research Council.
Introduction
A major feature of Alzheimer’s disease is the 
accumulation in the brain of an amyloid-β peptide (Aβ), 
which aggregates to form oligomers, plaques, and 
cerebrovascular deposits.1 The putative key role of Aβ in 
the pathogenesis of Alzheimer’s disease led to 
immunotherapeutic strategies2–4 that aimed to reduce 
levels of Aβ in the brain. Active immunisation of mice 
genetically modiﬁ ed to develop Aβ plaques as they age 
with full-length Aβ (Aβ42) resulted in a reduction of 
plaque burden and improved cognitive function.2,5
A phase I clinical trial of immunisation of patients 
with Alzheimer’s disease with Aβ42 (AN1792; Elan 
Pharma ceuticals, Dublin, Ireland) showed that there is 
a highly variable, largely dose-independent, antibody 
response to AN1792 in addition to variable clearance of 
amyloid plaques.3,6–8 However, the relation between 
serum AN1792 antibody concentrations and the degree 
of plaque clearance is unknown. Although not designed 
to test eﬃ  cacy, short-term clinical outcomes were 
disappointing, with three of the four exploratory 
measures of clinical eﬃ  cacy showing no signiﬁ cant 
diﬀ erences between the treatment and placebo group 
during the initial study period.3
A subsequent phase IIa study, halted when 6% of the 
patients developed meningoencephalitis,9 showed no 
major diﬀ erences in cognitive performance when 
antibody responders were compared with the placebo 
group at 1 year, despite evidence of high serum 
antibodies to Aβ42 in a subset of those who received 
active treatment.10 Whether active Aβ42 immunisation 
results in longer-term cognitive or survival beneﬁ ts is 
unknown. Additionally, although studies9,11–14 have raised 
concerns about the long-term safety of these approaches, 
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no long-term data on the survival rates or the cause of 
death in study populations have been published. Our 
aim was to examine the relations between AN1792 drug 
dose, Aβ42 antibody response, clinical outcomes after 
6 years, and neuropathological evidence of Aβ plaque 
removal.
Methods
Patients
Patients who met National Institute of Neurological and 
Communicative Disorders and Stroke–Alzheimer’s Dis-
ease and Related Disorders Association (NINCDS-
ADRDA) criteria15 for probable Alzheimer’s disease 
with mild to moderate dementia (14–26 points on the 
mini-mental state examination [MMSE]16) were eligible 
to enter this randomised, placebo-controlled, 
double-blind trial of active immunisation with an Aβ42 
synthetic peptide (AN1792).3 80 patients were enrolled, 
of whom 64 were randomly assigned to receive either 
50 μg or 225 μg AN1792 with an adjuvant (QS-21); 
16 individuals were randomly assigned to receive 
adjuvant alone. In a subsequent protocol extension 
phase, during which further injections were given of a 
modiﬁ ed formulation containing 0·4% polysorbate 80 
with the aim of increasing solubility of the Aβ peptide,3 
51 patients from the active treatment group received 
AN1792 in the modiﬁ ed formulation (25 patients 
received 50 μg, 26 received 225 μg) and 13 patients from 
the control group received adjuvant alone in the 
modiﬁ ed formulation. The total study treatment period 
was 84 weeks. Study enrolment, based at four sites in 
the UK (Southampton, Bath, Swindon, and Cardiﬀ ), 
began in April, 2000, and was completed by 
September, 2000, with the last study entrant ﬁ nishing 
the study in June, 2002.
After obtaining ethical approval in June, 2003, all 
80 patients (or their carers) enrolled in the original 
study were identiﬁ ed by the original study centre 
investigators and contacted in person. When study 
participants were reported as having died, conﬁ rmation 
of the date and cause of death was determined by access 
to public records from the UK General Register Oﬃ  ce 
(Southport, UK). Consent for post-mortem neuro-
pathological examination was sought from the carers 
of these patients. Surviving patients, or their carers, 
were approached for consent for further clinical 
follow-up, post-mortem neuropathological examination, 
or both.
Procedures
Patients who consented to participation in the follow-up 
phase were assessed at yearly intervals, whenever 
possible coincident with the month of their initial 
baseline assessment in the original treatment study, 
until the end of the follow-up study or until death. 
Clinical assessments were done by the same rater as in 
the original study and used the same clinical scales (the 
Alzheimer’s disease assessment scale cognitive subscale 
[ADAS-Cog];17 MMSE, and the disability assessment for 
dementia [DAD]18). These cognitive and functional 
assessments were used as a basis for rating the severity 
of dementia in accordance with the International 
Classiﬁ cation of Diseases version 10 diagnostic criteria.19 
All participants deﬁ ned as having severe dementia had 
MMSE scores of 10 points or less.
Because no patients in the placebo group had a post 
mortem during the follow-up study, we needed an alter-
native unimmunised control group of individuals with 
Alzheimer’s disease for histological comparisons of Aβ 
load. Unimmunised control cases, closely matched for 
age at death with the immunised cases, were obtained 
from the neuropathology archives of Southampton 
General Hospital. All control cases had a history of 
progressive dementia and satisﬁ ed consensus criteria 
for Alzheimer’s disease.20 The formalin-ﬁ xed brains 
were examined macroscopically and samples taken for 
histology from frontal, temporal, parietal, and occipital 
lobes, striatum, thalamus, brainstem, and cerebellum. 
The brain tissue was ﬁ xed, processed for histology, and 
stained in the same laboratory. Routine neuropathological 
assessment was done on sections stained with 
haematoxylin and eosin, modiﬁ ed Bielschowsky silver 
impregnation, and immunostaining done for Aβ and 
tau.
Two diﬀ erent assessments were made of Aβ in the 
cerebral cortex. Percentage Aβ load—ie, the percentage 
area of the cortex with Aβ immunostaining (clone 
6F/3D, an antibody that recognises aminoacid residues 
8–17 of the Aβ peptide; Novocastra, Newcastle, UK)—
was measured on consecutive 1·25× objective ﬁ elds of 
frontal, parietal, and temporal neocortex, by use of the 
KS400 3.0 image analysis system (Carl Zeiss). This 
measurement of Aβ load has the advantage of being 
quantitative, but is known to have considerable 
variability in Alzheimer’s disease6 and we have no 
knowledge of the starting values before immunisation 
for each patient.
We also looked for speciﬁ c histological evidence that 
plaques had been removed. Positive evidence of plaques 
having been removed was deﬁ ned by the presence of a 
constellation of histological features as described 
previously,7 including residual plaque cores in 
plaque-free areas, moth-eaten appearance of remaining 
plaques, phagocytosed Aβ within microglia, marked 
cerebral amyloid angiopathy, association of Aβ with 
capillaries in plaque-free areas, and resolution of 
tau-containing dystrophic neurites. Such evidence of 
plaque removal was assessed throughout all brain 
regions sampled for histology and was scored 
semi-quantitatively as minimal (ie, none or early 
process of removal), intermediate (ie, moderate or 
patchy), or very extensive (ie, virtually complete removal 
of plaques). This assessment was done in all cases, 
blind to cognitive function and antibody titres, by the 
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same neuropathologist (JARN). Although this assess-
ment is semi-quantitative, it relies on the presence of 
histological features that are speciﬁ c features of the 
response to Aβ immunisation in Alzheimer’s disease.7
Mean anti-AN1792 antibody titres were derived from 
the original study data, supplied by Elan Pharmaceuticals, 
and were deﬁ ned as the total serum anti-AN1792 
antibody titre in ELISA units3 over the treatment period 
for each participant divided by the number of assays 
done for that individual.
Additionally, blood samples were obtained from 
15 consenting AN1792-treated survivors at 5 or 6 years 
after their baseline assessment and from an age and 
cognitively (MMSE score) matched non-immunised 
Alzheimer’s disease (NINCDS-ADRDA probable 
criteria) control group (n=15), since we had too few 
samples from individuals who received placebo in the 
original trial. Total serum anti-Aβ antibody titres were 
determined with an ELISA assay developed in our 
laboratory. Values described are for combined bound 
and free levels of anti-Aβ42 antibody. The concentration 
of anti-Aβ42 antibody (in μg/mL) was calculated with a 
four-parameter curve-ﬁ t equation for the anti-Aβ42 
antibody (clone 21F12, Elan Pharmaceuticals) standard 
curve as described previously.21
Statistical analysis
Time from the ﬁ rst immunisation dose (with AN1792 
or placebo) to death, loss to clinical follow-up, or to the 
data censoring date—Sept 1, 2006, 6 years after the last 
patient had been entered into the trial—was analysed 
with a multivariable Cox proportional-hazards model. 
Ran dom isation was determined on the date of immun-
isation. Age and baseline cognitive state (ADAS-Cog 
score) at the start of the treatment study were entered 
as predictive variables. Diﬀ erential survival was 
examined with dose of vaccine (placebo; 50 μg or 225 μg 
AN1792) and, in a separate analysis, mean anti-AN1792 
80 subjects enrolled
into phase I study
Phase I study completed
20 patients dead at start
of follow-up study
(2 post mortems)
15 treated
5 placebo
36 patients and/or carers
agree to clinical follow-up
and/or post mortem
10 patients dead
(7 post mortems)
10 treated
0 placebo
26 patients alive
20 treated
6 placebo
September, 2000
Treatment study
commenced
June, 2002
Treatment study
completed
June, 2003
Follow-up study
commenced
September, 2006
Follow-up study
completed
24 patients and/or carers
refused consent for
clinical follow-up
12 patients dead
9 treated
3 placebo
12 patients alive
10 treated
2 placebo
Figure 1: Trial proﬁ le
Baseline MMSE 
(points)
AN1792 dose 
(μg)
Mean antibody 
response (ELISA units) 
Evidence of Aβ 
plaque removal*
Aβ load Braak tau 
stage†
Survival time 
(months)
MMSE before 
death (points)
1‡ 16 50 <1:100 None 2·76% V 4 16
2 15 225 <1:100 None 2·52% VI 41 0
3 21 50 1:119 Intermediate 0·75% VI 20 0
4 16 225 1:4072 Intermediate 6·65% VI 44 0
5 25 50 1:1707 Intermediate 2·19% VI 57 0
6 21 225 1:491 Intermediate 1·18% VI 63 0
7 23 50 1:4374 Very extensive 0·12% VI 60 0
8 20 50 1:6470 Very extensive 0·35% VI 64 0
MMSE=mini-mental state examination. *None=none or early process of plaque removal; intermediate=moderate/patchy removal of plaques; very extensive=virtually 
complete removal of plaques. †Of the unimmunised controls, seven were Braak stage VI, one was stage V. ‡Patient died suddenly after a ruptured abdominal aortic aneurysm.
Table 1: Aβ plaque removal and clinical characteristics of participants who had received AN1792 and who had post-mortem neuropathology
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antibody titres in ELISA units found over the treatment 
study period (0–84 weeks) (placebo; <1:100; 1:100 to 
1:4000, and >1:4000 ELISA units). This second analysis 
was based on the neuropathological ﬁ ndings that an 
antibody titre of less than 1:100 ELISA units was 
associated with no completed plaque removal, an 
antibody titre over 1:100 ELISA units was associated 
with the presence of areas of completed plaque removal, 
and an antibody titre over 1:4000 ELISA units was 
associated with very extensive plaque removal. This 
analysis was deemed to be exploratory in view of the 
small numbers involved. Similar analyses were done 
examining the time from the start of immunisation 
(with AN1792 or placebo) to the development of severe 
dementia or to the point of data censoring.
Assessment of normality of the variables Aβ load, 
anti-AN1792 antibody titre, change in ADAS-Cog, DAD, 
MMSE, and age at death were determined by 
quantile–quantile plots of the residuals. SPSS software 
(version 14) was used for all analyses.
Role of the funding source
Neither the funders of the follow-up study, nor the 
original phase I clinical trial, had a role in the design or 
conduct of the study, or in the collection, analysis, or 
interpretation of the data. All authors had full access to 
all the data; the corresponding author had ﬁ nal 
responsibility for the decision to submit for 
publication.
Results
The trial proﬁ le is shown in ﬁ gure 1. The mean age 
at baseline of the 20 participants who had died before 
the start of follow-up was 73·8 (SD 5·3) years; their 
mean ADAS-Cog at baseline was 28·8 (11·6) points. 
The mean  age at baseline of the 24 participants who 
refused consent to long-term clinical follow-up was 
73·5 (6·9) years and their mean ADAS-Cog score at 
baseline was 22·3 (11·0) points. The mean age at 
baseline of the 36 participants who consented to 
long-term clinical follow-up was 73·1 (8·6) years; their 
mean ADAS-Cog score at baseline was 22·2 (9·6) points. 
By the data censoring date, a further 22 participants had 
died; 38 individuals were conﬁ rmed as survivors 
(ﬁ gure 1). There was no loss to mortality or clinical 
follow-up.
By the data censoring date, nine of the participants 
who had consented to post-mortem examination had 
died and all had been examined neuropathologically. 
All nine had received AN1792 in the phase I study. In 
one participant, who had received 50 μg AN1792, the 
neuropathological assessment indicated a diagnosis of 
progressive supra nuclear palsy, on the basis of neuronal 
tangles mainly in the brainstem and basal ganglia. 
Neuronal tangles were sparse in the cerebral neocortex 
and absent from the hippocampus. The neuro-
pathological diagnosis was supported on review of the 
clinical records. This participant was excluded from 
further neuropathological analysis. The remaining 
eight cases satisﬁ ed the criteria for Braak stage V/VI 
consistent with a diagnosis of Alzheimer’s disease 
(table 1).
There was no diﬀ erence in age at death between the 
eight immunised participants who were examined 
neuropathologically and the unimmunised histological 
controls (75·3 [SE 3·1] years vs 79·1 [2·4] years; mean 
diﬀ erence 3·8 years, 95% CI –4·5 to 12·2; t test p=0·3). 
Unimmunised
Case 3
MMSE 0
Case 6
MMSE 0
Case 1
MMSE 16
Case 4
MMSE 0
Case 7
MMSE 0
Case 2
MMSE 0
Case 5
MMSE 0
Case 8
MMSE 0
Figure 2: Histological patterns of Aβ in the temporal lobe neocortex after immunisation with AN1792
An unimmunised control (top left) has a high density of plaques. Cases 1–8 are all patients who were 
immunised with Aβ42. Case 1 died 4 months after the ﬁ rst immunisation dose and showed an early stage of Aβ 
removal. Cases 2–8 survived 20–64 months after ﬁ rst immunisation dose. Case 2 did not develop anti-Aβ 
antibodies and showed no evidence of plaque clearance. Cases 3–6 showed an intermediate range of plaque 
clearance. Cases 7 and 8 showed very extensive (case 8) to nearly complete (case 7) removal of Aβ plaques 
throughout the cerebral cortex. All the long-term survivors (ie, cases 2–8) continued to have progressive 
dementia with cognitive function declining to an unrecordable level (ie, MMSE=0) before death. Scale 
bar=0·5 mm.
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Figure 3: Mean antibody response to AN1792 and Aβ plaque removal
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In the eight immunised participants, mean Aβ load was 
lower than in the unimmunised controls (2·1% [SE 0·7] 
in the treated participants vs 5·1% [0·9] in the controls; 
mean diﬀ erence 3·0%, 95% CI 0·6–5·4; t test p=0·02). 
However, there was considerable variation both in the 
Aβ load and in the degree of plaque removal among the 
immunised participants (table 1 and ﬁ gure 2). There 
was no evidence of a relation between AN1792 dose and 
Aβ load or plaque removal (AN1792 dose comparison 
with Aβ load Mann-Whitney U p=0·3; AN1792 dose 
comparison with Aβ plaque removal χ² 0·7, df 2, p=0·6; 
table 1). However, the degree of plaque removal varied 
signiﬁ cantly with mean antibody response attained 
during the treatment study period—ie, up to 84 weeks 
after the ﬁ rst dose (Kruskal-Wallis p=0·02, one-tailed; 
ﬁ gure 3). Two participants with the least evidence of 
plaque removal had a mean antibody response below 
the detectable range of the assay (<1:100; table 1). 
However, one of these individuals, despite the absence 
of a documented IgG antibody response during the 
study period, and a fairly high Aβ load, had clear 
evidence that acute mobilisation of plaque Aβ had 
started by the time he died.7 Overall, the mean antibody 
response during the treatment period showed a 
non-signiﬁ cant inverse correlation with post-mortem 
Aβ load (Spearman rank –0·52, p=0·09, one tailed; 
table 1).
All eight immunised participants had mild to 
moderate dementia at the start of the study (table 1). 
One of them, with a mean antibody response below the 
detectable range of the assay (<1:100), died suddenly 
after rupture of an abdominal aortic aneurysm 4 months 
after the study had begun, with a last recorded MMSE 
score of 16. All of the other seven recipients, including 
the two with post-mortem evidence of almost complete 
Aβ plaque removal, had severe end stage dementia in 
the absence of any pre-terminal acute confusional state 
(MMSE score 0) at their last examination before death 
(table 1 and ﬁ gure 2).
Of the 42 (53%) participants who had died by the data 
censoring date, the most common causes of death cited 
from all listed causes, in addition to dementia, were 
bronchopneumonia (13 patients, 31%), cerebrovascular 
accident (ﬁ ve, 12%), and myocardial infarction (two, 
5%). Other causes of death included a ruptured aortic 
aneurysm, pulmonary embolism, carcinoma of the 
breast, carcinoma of the bronchus, and carcinoma of 
the pancreas (one death each). No patients died from 
meningoencephalitis. Only one patient had clinical 
features of meningoencephalitis similar to those 
described in the phase II trial.4
By the data censoring date, 34 (53%) of the 
64 individuals in the treated group and eight (50%) of 
the 16 individuals in the placebo group had died (χ² 0·1, 
p=0·8). Median survival time was 66 (IQR 41–91) months 
for the AN1792 treated group and 50 (31–69) months for 
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Figure 4: Kaplan-Meier estimates of survival time to death by treatment group
Survival time 
hazard ratio 
(95% CI)* 
p value Time to severe 
dementia hazard 
ratio (95% CI)* 
p value
AN1792 treatment dose group (n=16 in placebo group)
50μg (n=32) 0·84 (0·36–1·95) 0·7 1·43 (0·49–4·20) 0·5
225μg (n=32) 0·78 (0·33–1·85) 0·6 0·96 (0·35–3·10) 0·9
Mean antibody response†  (n=16 in placebo group)
<1:100 (n=25) 0·80 (0·33–1·96) 0·6 1·03 (0·32–3·31) 1·0
1:100 to ≤1:4000 
(n=33)
0·72 (0·30–1·70) 0·5 1·15 (0·40–3·30) 0·8
>1:4000 (n=6) 1·50 (0·45–5·04) 0·5 3·07 (0·7–13·45) 0·1
*Cox regression analysis adjusted for baseline cognitive state (ADAS-Cog) and 
age. †Mean antibody response in ELISA units.
Table 2: Long-term survival and cognitive outcomes by treatment dose 
and mean antibody titre compared with placebo group
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Figure 5: Kaplan-Meier estimates of time to severe dementia by 
treatment group
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the placebo group. There was no evidence of diﬀ erences 
in survival time between the treated and placebo groups 
(hazard ratio 0·93, 95% CI 0·43–3·11; p=0·86; ﬁ gure 4). 
Likewise, there was no diﬀ erence in survival time after 
correction for cognitive state and age at the start of the 
study (0·81, 0·37–1·77; p=0·6). Cox regression analyses 
of survival time, with correction for cognitive state and 
age at the start of the study, showed no evidence of 
diﬀ erences in survival time by treatment dose group or 
by mean antibody response compared with the placebo 
group (table 2).
15 participants—12 in the AN1792 group and three in 
the placebo group—had progressed to severe dementia 
by the start of the follow-up study; a further 13 had 
progressed by the data censoring date. Thus, by 
treatment group, 23 (36%) of 64 individuals in the 
AN1792 treated group (13 in the 50 μg group, ten in the 
225 μg group) and ﬁ ve (31%) of 16 (31%) individuals in 
the placebo group had progressed to severe dementia 
by the end of the follow-up period (χ² 0·1, p=0·7). There 
was no diﬀ erence in the time to severe dementia 
between the treated and placebo groups (hazard 
ratio 1·18, 95% CI 0·45–3·11; p=0·73; ﬁ gure 5). 
Likewise, there was no diﬀ erence in time to severe 
dementia after correction for cognitive state and age at 
the start of the study (1·22, 0·46–3·27; p=0·7). Cox 
regression analysis of time to severe dementia, with 
correction for cognitive state and age at start of study, 
showed no evidence of diﬀ erences in time to severe 
dementia by treatment group or by mean antibody titre 
compared with the placebo group (table 2).
At the data censoring date, the 26 surviving 
participants who consented to long-term clinical 
follow-up had a mean ADAS-Cog score of 43·7 (SD 22·8) 
points, a mean MMSE score of 12·5 (8·9), and a mean 
DAD score of 30·4 (27·1), compared with mean scores 
at baseline at the start of the treatment study 
of 19·6 (5·8), 22·3 (2·7), and 76·9 (16·8), respectively. 
There was no evidence of a diﬀ erence in decline over 
the 6-year follow-up period for any of these outcome 
measures between the treatment group and the placebo 
group (table 3).
A blood serum sample for anti-Aβ antibody assays 
was obtained in 15 (75%) of the 20 AN1792-treated 
survivors at 5 or 6 years (mean 63 [SD 4] months) after 
baseline assessment and compared with 15 control 
individuals with Alzheimer’s disease matched by age 
and MMSE (age 77·1 [SD 8·6] years; MMSE 14·0 
[8·4] points). Eight cases had been treated with 225 µg 
and seven with 50 µg AN1792. The mean anti-Aβ 
antibody titre was raised in those treated with AN1792 
compared with the control individuals (232 [SE 56] 
µg/mL vs 79 [26] µg/mL; t test p=0·02). Anti-Aβ antibody 
titres at long-term follow-up showed a modest positive 
correlation with the mean anti-AN1792 antibody titres 
found during the initial treatment study period 
(Spearman rank 0·52, p=0·048). No correlations were 
found between anti-Aβ antibody titres at long-term 
follow-up and rate of decline as measured by ADAS-Cog; 
MMSE, or DAD at 6-year follow-up (all cases Spearman 
rank p>0·1).
Discussion
These data show that immunisation of patients with 
Alzheimer’s disease with Aβ42 (AN1792) is associated 
with a long-term reduction in Aβ load and a variable 
degree of plaque removal compared with unimmunised 
control individuals. Although the degree of plaque 
removal was variable, immunisation seems to initiate a 
long-term process, with post-mortem evidence of 
plaque removal 5 years after the last injection; further, 
in the survivors, there is evidence of persistently raised 
serum antibodies to Aβ correlating with the initial 
mean antibody response. The limited number of 
autopsy cases means that the correlations found 
between the measures of Aβ load, plaque removal, and 
mean antibody response to AN1792 should be viewed 
with caution. However, the two patients who had almost 
complete elimination of plaques, and the lowest Aβ 
loads, also had the highest mean AN1792 antibody 
response during the treatment phase of the study.
Despite the evidence of disease modiﬁ cation, there is 
little evidence to suggest that there is any major eﬀ ect 
on cognitive function. All but one of the individuals 
who died during the follow-up phase had clear end 
stage dementia before death, including the two 
individuals with the highest mean antibodies to Aβ and 
almost complete elimination of plaques. These ﬁ ndings 
imply that progressive neurodegeneration can occur in 
Alzheimer’s disease despite removal of plaques.
Cox regression analysis showed no evidence of 
immunisation having any eﬀ ect on long-term survival or 
clinical outcomes. However, the small numbers of 
participants enrolled in the initial study greatly limit the 
n Baseline observed 
mean (SD)
6 year follow-up
Observed mean change 
from baseline (SD)
Diﬀ erence in mean 
(95% CI)
p value
ADAS-Cog
Placebo 6 18·8 (2·2) 23·3 (18·9) –1·0 (–19·7 to 17·8) 0·9
AN1792 20 19·8 (6·6) 24·3 (19·6)
MMSE
Placebo 6 23·2 (2·3) –11·7 (9·4) –2·4 (–10·5 to 5·8) 0·5
AN1792 20 22·1 (2·8) –9·3 (8·2)
DAD
Placebo 6 81·8 (16·5) –43·7 (31·9) 3·6 (–23·6 to 30·9) 0·8
AN1792 20 75·4 (17·0) –47·3 (27·3)
ADAS-Cog=Alzheimer’s disease assessment scale—cognitive subscale. DAD=disability assessment for dementia. 
MMSE=mini-mental state examination. 
Table 3: Eﬀ ect of AN1792 or placebo on exploratory measures in the assessable population at 6 year 
follow-up
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power of this study and a larger trial might have shown 
some small beneﬁ t that could not be detected with the 
cohort size examined here. Caution is also required in the 
interpretation of the cognitive outcomes of the cohort of 
consenting survivors at 6 year follow-up. Although baseline 
age and cognitive function were comparable, a greater 
proportion of those who did not consent to long-term 
follow-up died during the follow-up period than of those 
who consented (12 [50%] of 24 vs 10 [28%] of 36). The 
cognitive and functional decline of the consenting sur-
vivors might thus represent an underestimate of overall 
decline and, potentially, of possible diﬀ erences between 
groups. Similar considerations apply to the generalisability 
of the long-term antibody titres in the consenting survivors, 
since determining whether non-survivors and those who 
did not consent also had a persistent antibody response 
was not possible.
The results of this study suggest that plaque removal is 
not enough to halt progressive neurodegeneration in 
Alzheimer’s disease and prompt some intriguing 
challenges to the amyloid hypothesis. There are a number 
of possible explanations for these ﬁ ndings. First, the 
presence of Aβ plaques might be necessary to initiate, but 
not to maintain, progressive neuro degeneration. Previous 
studies have shown a poor correlation between Aβ plaque 
load and the presence of dementia. For example, a 
substantial proportion of elderly individuals have Aβ 
plaques in equivalent densities to patients with Alzheimer’s 
disease but remain cognitively intact.22,23 Furthermore, 
recent reports in early Alzheimer’s disease show that 
amyloid load as measured with an in-vivo imaging probe 
does not change as the clinical condition deteriorates.24
Second, although some animal studies suggest that 
Aβ plaque removal can occur within days of the injection 
of anti-Aβ antibodies into the brain,25 other studies 
suggest that plaque removal occurs progressively over a 
period of months.26 The removal of plaques after AN1792 
immunisation could thus be a slow process in human 
beings with Alzheimer’s disease. Although there was 
evidence that Aβ mobilisation could start within 
4 months of immunisation, very extensive plaque 
removal was only present in those patients who survived 
to 60 months or longer after immunisation.
Third, much attention has been paid to the role of 
oligomeric Aβ, rather than ﬁ brillar Aβ in plaques, as the 
immediate cause of synaptic dysfunction and dementia 
in Alzheimer’s disease.27,28 Immunisation could fail to 
reduce the concentration of oligomeric Aβ and the 
concentration might even be increased during the active 
phase of disintegration of Aβ plaques.29 According to this 
view, aggregated Aβ in the form of plaques is harm less, 
or could even be protective, and therefore the pro cess of 
removing them might be counterproductive.
Fourth, vaccination with full-length Aβ could result 
in over-activation of the innate immune system.30,31 Both 
AN1792 and its adjuvant QS-21 have been shown to 
elicit a pro-inﬂ ammatory Th1 response32 that might 
thereby compromise any potential improvements that 
plaque removal could bring. Indeed, although not 
statistically signiﬁ cant, participants in this study with 
high antibody titres had a more rapid clinical 
progression than did those with moderate antibody 
titres. Whether these participants also had a marked 
Th1 response has not yet been examined.
On the basis of the results of this long-term follow-up 
study of patients with Alzheimer’s disease who were 
immunised with Aβ42, it is likely that the modiﬁ ed 
immunisation protocols currently in clinical trials 
will also result in removal of plaques from brains aﬀ ected 
by Alzheimer’s disease and could prove to be safer 
strategies. However, our ﬁ ndings suggest that removal 
of Aβ plaques might not be suﬃ  cient to prevent the 
progressive neurodegeneration in Alzheimer’s disease.
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